Meta-analysis and metagenes

References

• Spivey TL, Uccellini L, Ascierto ML, Zoppoli G, De Giorgi V, Delogu LG, Engle AM, Thomas JM, Wang E, Marincola FM, et al. Gene expression profiling in acute allograft rejection: challenging the immunologic constant of rejection hypothesis. J Transl Med 2011; 9:174; http://dx.doi.org/10.1186/1479-5876-9-174; PMID: 21992116
   PubMed Web of Science ®Google Scholar
• Bedognetti D, Wang E, Sertoli MR, Marincola FM. Gene-expression profiling in vaccine therapy and immunotherapy for cancer. Expert Rev Vaccines 2010; 9:555 - 65; http://dx.doi.org/10.1586/erv.10.55; PMID: 20518712
   PubMed Web of Science ®Google Scholar
• Galon J, Angell HK, Bedognetti D, Marincola FM. The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity 2013; 39:11 - 26; http://dx.doi.org/10.1016/j.immuni.2013.07.008; PMID: 23890060
   PubMed Web of Science ®Google Scholar
• Wang E, Bedognetti D, Marincola FM. Prediction of response to anticancer immunotherapy using gene signatures. J Clin Oncol 2013; 31:2369 - 71; http://dx.doi.org/10.1200/JCO.2013.49.2157; PMID: 23715576
   PubMed Web of Science ®Google Scholar
• Weiss GR, Grosh WW, Chianese-Bullock KA, Zhao Y, Liu H, Slingluff CL Jr., Marincola FM, Wang E. Molecular insights on the peripheral and intratumoral effects of systemic high-dose rIL-2 (aldesleukin) administration for the treatment of metastatic melanoma. Clin Cancer Res 2011; 17:7440 - 50; http://dx.doi.org/10.1158/1078-0432.CCR-11-1650; PMID: 21976537
   PubMed Web of Science ®Google Scholar
• Ji RR, Chasalow SD, Wang L, Hamid O, Schmidt H, Cogswell J, Alaparthy S, Berman D, Jure-Kunkel M, Siemers NO, et al. An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immunother 2012; 61:1019 - 31; http://dx.doi.org/10.1007/s00262-011-1172-6; PMID: 22146893
   PubMed Web of Science ®Google Scholar
• Bedognetti D, Spivey TL, Zhao Y, Uccellini L, Tomei S, Dudley ME, Ascierto ML, De Giorgi V, Liu Q, Delogu LG, et al. CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2. Br J Cancer 2013; 109:2412 - 23; http://dx.doi.org/10.1038/bjc.2013.557; PMID: 24129241
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Vacchelli E, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zucman-Rossi J, Zitvogel L, Kroemer G. Trial Watch: Monoclonal antibodies in cancer therapy. Oncoimmunology 2012; 1:28 - 37; http://dx.doi.org/10.4161/onci.1.1.17938; PMID: 22720209
   PubMed Web of Science ®Google Scholar
• Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, Chen S, Klein AP, Pardoll DM, Topalian SL, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012; 4:127ra37; http://dx.doi.org/10.1126/scitranslmed.3003689; PMID: 22461641
   PubMed Web of Science ®Google Scholar
• Tomei S, Wang E, Delogu LG, Marincola FM, Bedognetti D. Non-BRAF-targeted therapy, immunotherapy, and combination therapy for melanoma. Expert Opin Biol Ther 2014; Forthcoming http://dx.doi.org/10.1517/14712598.2014.890586; PMID: 24625306
   PubMed Web of Science ®Google Scholar
• Pescatori M, Bedognetti D, Venturelli E, Ménard-Moyon C, Bernardini C, Muresu E, Piana A, Maida G, Manetti R, Sgarrella F, et al. Functionalized carbon nanotubes as immunomodulator systems. Biomaterials 2013; 34:4395 - 403; http://dx.doi.org/10.1016/j.biomaterials.2013.02.052; PMID: 23507086
   PubMed Web of Science ®Google Scholar
• Stoll G, Enot D, Mlecnik B, Galon J, Zitvogel L, Kroemer G. Immune-related gene signatures predict the outcome of neoadjuvant chemotherapy. OncoImmunology 2014; 3:e27884
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity 2013; 39:74 - 88; http://dx.doi.org/10.1016/j.immuni.2013.06.014; PMID: 23890065
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Galluzzi L, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Kroemer G. Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology 2012; 1:179 - 88; http://dx.doi.org/10.4161/onci.1.2.19026; PMID: 22720239
   PubMed Web of Science ®Google Scholar
• Ignatiadis M, Singhal SK, Desmedt C, Haibe-Kains B, Criscitiello C, Andre F, Loi S, Piccart M, Michiels S, Sotiriou C. Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis. J Clin Oncol 2012; 30:1996 - 2004; http://dx.doi.org/10.1200/JCO.2011.39.5624; PMID: 22508827
   PubMed Web of Science ®Google Scholar
• Issa-Nummer Y, Loibl S, von Minckwitz G, Denkert C. Tumor-infiltrating lymphocytes in breast cancer: A new predictor for responses to therapy. OncoImmunology 2014; 3:e27926
   PubMedGoogle Scholar
• Gu-Trantien C, Loi S, Garaud S, Equeter C, Libin M, de Wind A, Ravoet M, Le Buanec H, Sibille C, Manfouo-Foutsop G, et al. CD4⁺ follicular helper T cell infiltration predicts breast cancer survival. J Clin Invest 2013; 123:2873 - 92; http://dx.doi.org/10.1172/JCI67428; PMID: 23778140
   PubMed Web of Science ®Google Scholar
• Gu-Trantien C, Willard-Gallo K. Tumor-infiltrating follicular helper T cells: The new kids on the block. Oncoimmunology 2013; 2:e26066; http://dx.doi.org/10.4161/onci.26066; PMID: 24244900
   PubMedGoogle Scholar
• Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, Angell H, Fredriksen T, Lafontaine L, Berger A, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 2013; 39:782 - 95; http://dx.doi.org/10.1016/j.immuni.2013.10.003; PMID: 24138885
   PubMed Web of Science ®Google Scholar
• Goc J, Fridman WH, Sautès-Fridman C, Dieu-Nosjean MC. Characteristics of tertiary lymphoid structures in primary cancers. Oncoimmunology 2013; 2:e26836; http://dx.doi.org/10.4161/onci.26836; PMID: 24498556
   PubMed Web of Science ®Google Scholar
• Iida N, Dzutsev A, Stewart CA, Smith L, Bouladoux N, Weingarten RA, Molina DA, Salcedo R, Back T, Cramer S, et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science 2013; 342:967 - 70; http://dx.doi.org/10.1126/science.1240527; PMID: 24264989
   PubMed Web of Science ®Google Scholar
• Wang E, Bedognetti D, Tomei S, Marincola FM. Common pathways to tumor rejection. Ann N Y Acad Sci 2013; 1284:75 - 9; http://dx.doi.org/10.1111/nyas.12063; PMID: 23651198
   PubMed Web of Science ®Google Scholar